Could a leukemia drug boost prostate cancer treatment?

NCT ID NCT06834321

Recruiting now Disease control Sponsor: baotai Liang Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This study tests whether adding the drug homoharringtonine to standard hormone therapy before prostate removal surgery can better shrink or eliminate tumors in men with locally advanced or limited-spread prostate cancer. About 96 men will receive either the combination or hormone therapy alone before surgery. The goal is to see if the combo leads to more complete tumor clearance and longer time without cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First People Hospital of Nantong City
RECRUITING

Nantong, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhongda Hospital
RECRUITING

Nanjing, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PROSTATE CA